Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Sinopep Allsino Bio Pharmaceutical Co's Return-on-Tangible-Equity or its related term are showing as below:
SHSE:688076'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -258.11 Med: 11.8 Max: 79.99
Current: 12.7
During the past 13 years, Sinopep Allsino Bio Pharmaceutical Co's highest Return-on-Tangible-Equity was 79.99%. The lowest was -258.11%. And the median was 11.80%.
SHSE:688076's Return-on-Tangible-Equity is ranked better than 88.25% of 1200
companies
in the Biotechnology industry
Industry Median: -42.305
vs SHSE:688076: 12.70
Sinopep Allsino Bio Pharmaceutical Co (SHSE:688076) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Sinopep Allsino Bio Pharmaceutical Co Return-on-Tangible-Equity Related Terms
Sinopep Allsino Bio Pharmaceutical Co Return-on-Tangible-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sinopep Allsino Bio Pharmaceutical Co Return-on-Tangible-Equity Chart
SHSE:688076 vs VRTX, REGN, ALNY: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, Sinopep Allsino Bio Pharmaceutical Co's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sinopep Allsino Bio Pharmaceutical Co Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sinopep Allsino Bio Pharmaceutical Co's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Sinopep Allsino Bio Pharmaceutical Co's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 21.28% mean?
Sinopep Allsino Bio Pharmaceutical Co (SHSE:688076) has a Return-on-Tangible-Equity of 21.28% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Sinopep Allsino Bio Pharmaceutical Co and its competitors. This is 80% above median its historical median of 11.80. According to the industry distribution chart, Sinopep Allsino Bio Pharmaceutical Co ranks #141 out of 1200 companies in the Biotechnology industry, placing it in the top 11.7%.
Is Sinopep Allsino Bio Pharmaceutical Co's Return-on-Tangible-Equity too high?
Sinopep Allsino Bio Pharmaceutical Co's current Return-on-Tangible-Equity of 21.28% is 80% above median its 10-year median of 11.80. Based on the distribution chart, Sinopep Allsino Bio Pharmaceutical Co ranks #141 out of 1200 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Sinopep Allsino Bio Pharmaceutical Co has a GF Score™ of 69/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sinopep Allsino Bio Pharmaceutical Co's Return-on-Tangible-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Sinopep Allsino Bio Pharmaceutical Co ranks #141 out of 1200 companies for Return-on-Tangible-Equity. This places Sinopep Allsino Bio Pharmaceutical Co in the top 12% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Sinopep Allsino Bio Pharmaceutical Co and its competitors. Sinopep Allsino Bio Pharmaceutical Co's current Return-on-Tangible-Equity is 21.28%, which is 80% above median its own 10-year median of 11.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sinopep Allsino Bio Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Sinopep Allsino Bio Pharmaceutical Co (SHSE:688076) is currently considered Significantly Undervalued. The stock's GF Value™ is ¥58.20, compared to a current price of ¥26.33 — trading 54.8% below its estimated fair value. The current Return-on-Tangible-Equity is 21.28%, which is 80% above median its 10-year median of 11.80. Sinopep Allsino Bio Pharmaceutical Co's overall GF Score™ is 69/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Sinopep Allsino Bio Pharmaceutical Co (SHSE:688076), the current Return-on-Tangible-Equity is 21.28% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sinopep Allsino Bio Pharmaceutical Co (SHSE:688076) Overvalued in 2026?
Based on GuruFocus' analysis, Sinopep Allsino Bio Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥26.33 is trading 54.8% below its estimated GF Value™ of ¥58.20.
GuruFocus considers Sinopep Allsino Bio Pharmaceutical Co to be Significantly Undervalued.
Key valuation signals for SHSE:688076:
Return-on-Tangible-Equity: 21.28% (80% above median its 10-year median of 11.80)
GF Value™: ¥58.20 vs. price of ¥26.33 (54.8% below fair value)
No single metric tells the full story. See the SHSE:688076 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sinopep Allsino Bio Pharmaceutical Co Business Description
Sinopep Allsino Bio Pharmaceutical Co Ltd is a market-oriented, research and development and innovation-driven biomedical enterprise focusing on the research, development, production and sales of peptide drugs and small molecule chemical drugs.
69GF Score
Get the complete analysis for SHSE:688076
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688076 has been successfully added to your 
